• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Thailand·Consumer Cyclical·APCO.BK
Share

Asian Phytoceuticals Public Company Limited Stocks

THB 2.5Last Updated 22.10.2026

Issuer Rating

3/7
Performance

Average

Risk

Considerable

Recommendation

Sell

Market Cap

THB 45.24M

THB 2.5
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Asian Phytoceuticals Public Company Limited engages in the research and development, manufacture, and distribution of healthcare and natural extracts-based beauty products in Thailand. The company offers cream and lotion products in bottles and tubes for massage to tighten the skin and reduce the desired area, and facial lotion products; and products for reverse aging, anti-aging, and longevity. It is also involved in the research on mangosteen under the project name Operation BIM. It also exports its products. The company was formerly known as Natural Cosmetics Research Co., Ltd. and changed its name to Asian Phytoceuticals Public Company Limited in July 2005. Asian Phytoceuticals Public Company Limited was founded in 1988 and is headquartered in Lamphun, Thailand.

Company Valuation

Overvalued
2/7

From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. In particular, the stock is reasonably priced on P/E, of fair value on

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds have ramped up their bets against the euro to a 2020 high

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

24.10.2026 04:37

A key Novartis drug failed to meet expectations. The stock price fell

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026